ABSTRACT
Institutions preparing to perform sentinel lymph-node (SLN) biopsy for the treatment of patients with melanoma must first establish cooperation among clinicians from various departments. Surgeons and nuclear medicine physicians must discuss each SLN biopsy case in order to determine the preferred radiolabeled-tracer injection site. Surgeons require clear feedback concerning drainage sites and the number of SLNs detected by the labeled solution. The technique of lymphoscintigraphy (LSG) has been studied extensively during the past decades, and we now know that all cutaneous sites permit accurate mapping of the lymphatic drainage patterns.1-4 This point is important, because some tumors may have ambiguous nodal drainage or may drain to more than one nodal basin.
